Moolec Science S.A.

Moolec Science S.A.

MLEC
Moolec Science S.A.US flagNASDAQ Global Market
6.83
USD
-0.02
- -
4.96MMarket Cap
Moolec Science S.A.
MLEC
(NASDAQ Global Market)

Recent

price

8.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
- -
1,374.42
1,201.69
774.28
30.99
Revenue per Share
- -
-18.08
132.05
-84.22
-258.69
-32.77
Basic EPS, GAAP
- -
-7.53
-174.19
67.99
-5.49
-27.79
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-26.06
-190.22
4.49
-253.51
-276.5
Book Value per Share
- -
-11.96
4.36
-101.76
-367.01
-25.88
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
421
466
334
8
Sales/Revenue/Turnover
- -
- -
12.02
8.96
-1.05
-116.72
Operating Margin (%)
- -
- -
20
21
22
1
Depreciation Expense
- -
-5
40
-33
-111
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
9.61
-7.01
-33.41
-105.71
Profit Margin (%)
1
-3
-7
11
-205
3
Working Capital
- -
- -
- -
216
20
20
LT Debt
5
2
10
250
-83
3
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'24
Sep'25
Dec'25
ST Debt
238
4
3
LT Borrowings
208
18
19
LT Finance Leases
8
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
41
33
30

Working Capital

FRC

in mil. unless spec.
Jun'24
Sep'25
Dec'25
Total Current Assets
438
11
10
Cash, Cash Equivalents & STI
68
4
2
Accounts Receivable, Net
209
1
2
Inventories
126
6
5
Total Current Liabilities
427
7
6
Payables & Accruals
174
3
3
ST Debt
238
4
3
Deferred Revenue
4
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-133.15%
Free Cash Flow
- -
- -
-108.97%
Net Income, GAAP
- -
- -
241.01%
Sales/Revenue/Turnover
- -
- -
-28.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
- -
2
2
466
2025
2
3
- -
- -
334
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.31
-7.08
-5.57
-10.5
-84.22
2025
-7.43
-9.35
- -
- -
-258.69
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Moolec Science S.A. (NASDAQ: MLEC) is a science-based food ingredient company that develops real animal proteins and nutritional oils in plants through molecular farming technology; it produces animal proteins engineered into plant genomes to enhance functionality in taste, texture, and nutrition for applications in food, pet food, animal feed, and dietary supplements. Core products include VALORASOY™, a texturized soy protein mimicking meat texture sold to distributors and food producers worldwide from a 10,000-ton-per-year facility in Argentina; pipeline offerings such as Piggy Sooy™ (plant-based pork protein), GLASO™ (safflower oil rich in gamma-linolenic acid), SPC2 (plant-based chymosin), and YEEA1 (yeast biomass extract); and integrated solutions like Mycofood™ under the Eternal® brand for alternative proteins. The company operates across North and South America, Europe, the United States, United Kingdom, Netherlands, and Cayman Islands, with revenues primarily from Argentina-based operations; founded in 2020 with headquarters in Luxembourg at 17 Boulevard F.W. Raiffeisen. In a major strategic expansion completed in June 2025, Moolec closed a transformational business combination with Bioceres Group, Nutrecon, and Gentle Technologies Corp., issuing up to 87 million shares and 5 million warrants to integrate biological agriculture technologies including Rizobacter®, ProFarm®, and HB4® drought-tolerant seeds; advanced R&D, CDMO, and regulatory services via Agrality® and Synbio Powerlabs®; and emerging biomaterials and autonomous farming equipment. This all-stock transaction, announced in April 2025 and backed by 70% of shareholders, combines over 800 patents, 550 product registrations, and more than $500 million in annual sales across 50 countries, enabling portfolio diversification, operational synergies, and growth in regenerative agriculture, food-tech, and bioeconomy sectors. The deal positions Moolec to accelerate molecular farming commercialization while expanding upstream capabilities in climate-resilient crops and downstream manufacturing.

Company News

APIChat
  • Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States

  • Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period

  • Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applications

  • Moolec Science Announces Breakthrough in Molecular Farming With Successful Expression of Bovine Myoglobin in Pea Seeds

  • Moolec Science (MLEC) Projected to Post Earnings on Tuesday

  • Head-To-Head Review: Bioceres Crop Solutions (NASDAQ:BIOX) and Moolec Science (NASDAQ:MLEC)

  • Analyzing Moolec Science (NASDAQ:MLEC) & Dole (NYSE:DOLE)

  • Moolec Science (MLEC) Stock Explodes 90% After GLA Update

  • Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 Crushing

  • Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions

  • Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

  • Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

  • Moolec Science Announces Effectiveness of Share Consolidation

  • Moolec Receives Staff Determination Letter and Provides Update on Nasdaq Listing Compliance Status

  • Moolec Science SA Announces the Implementation of a Share Consolidation of Its Ordinary Shares, Par Value U.S.$0.10 Per Share (the "Shares")

  • Moolec Science Scales GLASO U.S. Platform With Record 2025 Campaign and Expansion Into Nutrition & Supplements Market

  • Reviewing Moolec Science (NASDAQ:MLEC) and CHS (NASDAQ:CHSCP)

  • Pyxus International (OTCMKTS:PYYX) and Moolec Science (NASDAQ:MLEC) Head to Head Comparison

  • Moolec Receives Nasdaq Determination Letter

  • Financial Review: Scheid Vineyards (OTCMKTS:SVIN) vs. Moolec Science (NASDAQ:MLEC)